Advertisement

Lymphocyte-Depleted Hodgkin Lymphoma

  • Roberto N. Miranda
  • Joseph D. Khoury
  • L. Jeffrey Medeiros
Chapter
Part of the Atlas of Anatomic Pathology book series (AAP)

Abstract

Lymphocyte-depleted (LD) Hodgkin lymphoma (HL) is a type of classical HL with a diffuse growth pattern characterized by Reed–Sternberg and Hodgkin (RS + H) cells, often with anaplastic features, and depletion of small lymphocytes. Amorphous fibrosis can be present. LD is the least common type of HL, representing less than 1 % of cases, and many cases once considered as LD in the past are classified currently as diffuse large B-cell lymphoma, anaplastic large cell lymphoma, or nodular sclerosis HL with LD. LDHL is more frequent in poor countries and in patients with human immunodeficiency virus (HIV) infection. Patients with LD are older, with a median age in the fifth decade, and a male to female ratio of approximately 2–1. Whites and blacks are equally affected. Most patients have advanced clinical stage disease and B symptoms. Although patients with LD have the most aggressive form of all types of HL, in the modern era of chemotherapy patients with LD respond similarly to patients with other types of HL and the 5-year survival among different types of CHL is uniform.

Keywords

Human Immunodeficiency Virus Overall Survival Hodgkin Lymphoma Anaplastic Large Cell Lymphoma Small Lymphocyte 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Slack GW, Ferry JA, Hasserjian RP, et al. Lymphocyte depleted Hodgkin lymphoma: an evaluation with immunophenotyping and genetic analysis. Leuk Lymphoma. 2009;50:937–43.PubMedCrossRefGoogle Scholar
  2. 2.
    Medeiros LJ, Greiner TC. Hodgkin’s disease. Cancer. 1995;75:357–69.PubMedCrossRefGoogle Scholar
  3. 3.
    Shimabukuro-Vornhagen A, Haverkamp H, Engert A, et al. Lymphocyte-rich classical Hodgkin’s lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin’s Study Group trials. J Clin Oncol. 2005;23:5739–45.PubMedCrossRefGoogle Scholar
  4. 4.
    Greer JP, Kinney MC, Cousar JB, et al. Lymphocyte-depleted Hodgkin’s disease. Clinicopathologic review of 25 patients. Am J Med. 1986;81:208–14.PubMedCrossRefGoogle Scholar
  5. 5.
    Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, et al. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood. 2002;100:3935–41.PubMedCrossRefGoogle Scholar
  6. 6.
    Aldinucci D, Gloghini A, Pinto A, et al. The classical Hodgkin’s lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol. 2010;221:248–63.PubMedCrossRefGoogle Scholar
  7. 7.
    Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med. 2010;362:875–85.PubMedCrossRefGoogle Scholar
  8. 8.
    Kapatai G, Murray P. Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma. J Clin Pathol. 2007;60:1342–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Klimm B, Franklin J, Stein H, et al. Lymphocyte-depleted classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin study group. J Clin Oncol. 2011;29:3914–20.PubMedCrossRefGoogle Scholar
  10. 10.
    Shenoy P, Maggioncalda A, Malik N, Flowers CR. Incidence patterns and outcomes for Hodgkin lymphoma patients in the United States. Adv Hematol. 2011;2011:725219.PubMedGoogle Scholar
  11. 11.
    Bazzeh F, Rihani R, Howard S, Sultan I. Comparing adult and pediatric Hodgkin lymphoma in the Surveillance, Epidemiology and End Results Program, 1988–2005: an analysis of 21,734 cases. Leuk Lymphoma. 2010;51:2198–207.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Roberto N. Miranda
    • 1
  • Joseph D. Khoury
    • 1
  • L. Jeffrey Medeiros
    • 1
  1. 1.Department of HematopathologyThe University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations